You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
申聯生物(688098.SH):IPO募投項目產品正式投產
格隆匯 02-10 09:04

格隆匯2月10日丨申聯生物(688098.SH)公佈,公司首次公開發行募投項目產品“豬口蹄疫O型、A型二價滅活疫苗(Re-O/MYA98/JSCZ/2013株+Re-A/WH/09株)”於近日獲得中華人民共和國農業農村部核發的產品批准文號批件,標誌着公司首次公開發行募集資金投資項目正式投產。產品銷售之前,除履行產品批簽發程序外,無需履行其他審批程序。

豬口蹄疫O型、A型二價滅活疫苗(Re-O/MYA98/JSCZ/2013株+ReA/WH/09株)於2013年開始由公司與中國農業科學院蘭州獸醫研究所、中農威特生物科技股份有限公司、金宇保靈生物藥品有限公司聯合研發,於2017年12月11日獲得國家一類新獸藥註冊證書。

該疫苗產品是公司首次公開發行募投項目“懸浮培養口蹄疫滅活疫苗項目”產品。募投項目總投資8.681億元,其中募集資金投資額4.4億元建設兩條懸浮培養口蹄疫滅活疫苗生產線,設計產能共2.5億頭份。其中第一條生產線已建設完成,於2019年2月通過GMP靜態驗收後進行試生產,於2020年5月通過了生物安全三級防護驗收和獸藥GMP驗收。該次取得產品批准文號後募投項目產品正式投產。第二條生產線基礎設施建設完成,設備尚未採購。

該疫苗產品使用公司擁有的行業先進的病毒滅活技術、細胞懸浮培養工藝、抗原濃縮純化等關鍵核心技術進行製備,顯著提高了抗原產量,提升了生產能力,降低了生產成本,同時具有良好的抗原性和免疫效力,具有較強的市場競爭力。該產品投產後,將提升公司的市場競爭力和行業地位。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account